Two novel NPM1 mutations in a therapy-responder AML patient

Hematological Oncology

Volumn 28, Issue 3, 2010, Pages 151-155

  Pianta, Annalisa ^a   Fabbro, Dora ^b   Damiani, Daniela ^b   Tiribelli, Mario ^b   Fanin, Renato ^b   Franzoni, Alessandra ^a   Romanello, Milena ^a   Tell, Gianluca ^a   Di Loreto, Carla ^b   Damante, Giuseppe ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

Author keywords

AML; Apoptosis; NPM1; Nucleolus; p53

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; MITOXANTRONE; NUCLEOPHOSMIN; NUCLEAR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CASE REPORT; CHROMOSOME ANALYSIS; DRUG MEGADOSE; EXON; FEMALE; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT RESPONSE; GENETICS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MUTATION; NUCLEOLUS;

CELL NUCLEOLUS; EXONS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; TRANSFECTION;

EID: 77957309010     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.906     Document Type: Article

References (27)

1. Eirin-Lopez JM, Frehlick LJ, Ausio J. Long-term evolution and functional diversification in the members of the nucleophosmin/ nucleoplasmin family of nuclear chaperones. Genetics 2006; 173: 1835-1850.
2. Okuda M, Horn HF, Tarapore P, et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 2000; 103: 127-140.
3. Sandeep SN, Olson MOJ. Effects of interphase and mitotic phosphorylation on the mobility and location of nucleolar protein B23. J Cell Sci 2006; 119: 3676-3685.
4. Grisendi S, Mecucci C, Falini B, Pandolfi PP, Nucleophosmin cancer. Nat Rev Cancer 2006; 6: 493-505.
5. Nozawa Y, Van Belzen N, Van der Made AC, Dinjens WN, Bosman FT. Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J Pathol 1996; 178: 48-52.
6. Bernard K, Litman E, Fitzpatrick JL, Shellman YG, Argast G, Polvinen K, et al. Functional proteomic analysis of melanoma progression. Cancer Res 2003; 63: 6716-6725.
7. Tsui KH, Cheng AJ, Chang PL, Pan TL, Yung BY. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma. Urology 2004; 64: 839-844.
8. Hayami R, Sato K, WuW, Nishikawa T, Hiroi J, Ohtani-Kaneko R, et al. Down-regulation of BRCA1-BARD1 ubiquitin ligase by CDK2. Cancer Res 2005; 65: 6-10.
9. Berger R, Busson M, Baranger L, Helias C, Lessard M, Dastugue N, et al. Loss of the NPM1 gene in myeloid disorders with chromosome 5 rearrangements. Leukemia 2006; 20: 319-321.
10. Falini B, Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood 2002; 99: 409-426.
11. Löwenberg B, Downing JR, Burnett AK. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-1062.
12. Schiffer CA. Hematopoietic growth factors and the future of therapeutic research on acute myeloid leukemia. N Engl J Med 2003; 349: 727-729.
13. Smith M, Bernett M, Bassan R, Gatta G, Tondini C, Kern W. Adult acute myeloid leukaemia. Crit Rev Oncol Hematol 2004; 50: 197-222.
14. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 2002; 3: 179-198.
15. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254-266. (Pubitemid 40110814)
16. Chan PK. Characterization and cellular localization of nucleophosmin/ B23 in HeLa cells treated with selected cytotoxic agents (studies of B23-translocation mechanism). Exp Cell Res 1992; 203(1): 174-181.
17. Falini B, Bolli N, Shang J, et al. Both carboxy-terminus NES motif and mutated tryptophans are crucial for aberrant nuclear exoprt of nucleophosmin leukemic mutants in NPMc+AML. Blood 2006; 107: 4514-4523.
18. Nishimura Y, Ohkubo T, Furuichi Y, Umekawa H. Tryptophans 286 and 288 in the C-terminal region of protein B23.1 are important for its nucleolar localization. Biosci Biotechnol Biochem 2002; 66(10): 2239-2242.
19. Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+AML): biological and clinical features. Blood 2007; 109: 874-885.
20. Wang W, Budhu A, Forgues M, Wang XW. Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol 2005; 7(8): 823-830.
21. Peter M, Nakagawa J, Doree M, Labbe JC, Nigg EA. Identification of major nucleolar proteins as candidate mitotic substrates of cdc2 kinases. Cell 1990; 60: 791-801.
22. Dundr M, Misteli T, Olson MO. The dynamics of postmitotic reassembly of the nucleolus. J Cell Biol 2000; 150: 433-446.
23. Gonda K, Wudel J, Nelson D, Katoku-Kikyo N, Reed P, Tamada H, Kikyo N. Requirement of the protein B23 for nucleolar disassembly induced by the FRGY2a family proteins. J Biol Chem 2006; 281: 8153-8160.
24. Amin MA, Matsunaga S, Uchiyama S, Fukui K. Depletion of nucleophosmin leads to distortion of nucleolar and nuclear structure in HeLa cells. Biochem J 2008; 415(3): 345-351.
25. Rubbi CP, Milner J. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J 2003; 22(22): 6068-6077.
26. Colombo E, Marine J-C, Danovi D, et al. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 2002; 4: 529-533.
27. Döhner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics-interaction with other gene mutations. Blood 2005; 106: 3740-3746.